Original language | English |
---|---|
Journal | Geriatrics and Gerontology International |
DOIs | |
Publication status | Accepted/In press - 2022 |
All Science Journal Classification (ASJC) codes
- Health(social science)
- Gerontology
- Geriatrics and Gerontology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Frailty screening index and atrial fibrillation outcomes in the All Nippon AF In the Elderly registry. / Akishita, Masahiro; Suzuki, Shinya; Inoue, Hiroshi et al.
In: Geriatrics and Gerontology International, 2022.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Frailty screening index and atrial fibrillation outcomes in the All Nippon AF In the Elderly registry
AU - Akishita, Masahiro
AU - Suzuki, Shinya
AU - Inoue, Hiroshi
AU - Akao, Masaharu
AU - Atarashi, Hirotsugu
AU - Ikeda, Takanori
AU - Koretsune, Yukihiro
AU - Okumura, Ken
AU - Shimizu, Wataru
AU - Tsutsui, Hiroyuki
AU - Toyoda, Kazunori
AU - Hirayama, Atsushi
AU - Yasaka, Masahiro
AU - Yamaguchi, Takenori
AU - Teramukai, Satoshi
AU - Kimura, Tetsuya
AU - Morishima, Yoshiyuki
AU - Takita, Atsushi
AU - Yamashita, Takeshi
N1 - Funding Information: We thank all individuals (physicians, nurses, institutional staff and patients) involved in the ANAFIE Registry. We also thank IQVIA Services Japan K.K. and EP‐CRSU for their partial support in the conduct of this registry, which was funded by Daiichi Sankyo Co., Ltd., in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ). In addition, the authors thank Daisuke Chiba of Daiichi Sankyo Co., Ltd. for support in the preparation of the manuscript. This work was supported by Daiichi Sankyo Co., Ltd. Funding Information: MAki received research funding from Astellas, Bayer Healthcare, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Kracie Pharma, Merck Sharp & Dohme, Mitsubishi Tanabe, Ono Pharmaceutical, Takeda, Teijin Pharma, and Tsumura, and remuneration from Daiichi Sankyo and Merck Sharp & Dohme. SS received remuneration from Bristol‐Myers Squibb and Daiichi Sankyo. HI received remuneration from Daiichi Sankyo, Bayer and Bristol‐Myers Squibb, and consultancy fee from Daiichi Sankyo. MAka received research funding from Bayer and Daiichi Sankyo, and remuneration from Bristol‐Myers Squibb, Nippon Boehringer Ingelheim, Bayer and Daiichi Sankyo. HA received remuneration from Daiichi Sankyo. TI received research funding from Daiichi Sankyo and Bayer, and remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim and Bristol‐Myers Squibb. YK received remuneration from Daiichi Sankyo, Bristol‐Myers Squibb and Nippon Boehringer Ingelheim. KO received remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson and Medtronic. WS received research funding from Bristol‐Myers Squibb, Daiichi Sankyo and Nippon Boehringer Ingelheim, and remuneration from Daiichi Sankyo, Pfizer Japan, Bristol‐Myers Squibb, Bayer and Nippon Boehringer Ingelheim. HT received research funding from Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, IQVIA Services Japan, MEDINET, Medical Innovation Kyushu, Kowa, Daiichi Sankyo, Johnson & Johnson and NEC, consulting fee from Novartis Pharma, Ono Pharmaceutical, Bayer and Nippon Boehringer Ingelheim, remuneration from Kowa, Teijin Pharma, Nippon Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Pfizer Japan, Ono Pharmaceutical, Daiichi Sankyo, Novartis Pharma, Bayer, Otsuka Pharmaceutical, AstraZeneca and Nippon Rinsho, and leadership or fiduciary role in Japanese Heart Failure Society. KT received remuneration from Daiichi Sankyo, Bayer, Bristol‐Myers Squibb, Otsuka, Novartis and Abbott Medical. AH participated in a course endowed by Boston Scientific Japan, has received research funding from Daiichi Sankyo and Bayer, and remuneration from Bayer, Daiichi Sankyo, Bristol‐Myers Squibb and Nippon Boehringer Ingelheim. MY received remuneration from Nippon Boehringer Ingelheim and Daiichi Sankyo. TYamag acted as an Advisory Board member of Daiichi Sankyo, and received remuneration from Daiichi Sankyo and Bristol‐Myers Squibb. ST received research funding from Nippon Boehringer Ingelheim, and remuneration from Daiichi Sankyo, Sanofi, Takeda, Chugai Pharmaceutical, Solasia Pharma, Bayer, Sysmex, Nipro, NapaJen Pharma, Gunze and Atworking. TK, YM and AT are employees of Daiichi Sankyo. TYamas received research funding from Bristol‐Myers Squibb, Bayer and Daiichi Sankyo, manuscript fees from Daiichi Sankyo and Bristol‐Myers Squibb, and remuneration from Daiichi Sankyo, Bristol‐Myers Squibb, Bayer, Ono Pharmaceutical, Novartis, Otsuka Pharmaceutical and Toa Eiyo.
PY - 2022
Y1 - 2022
UR - http://www.scopus.com/inward/record.url?scp=85136491959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136491959&partnerID=8YFLogxK
U2 - 10.1111/ggi.14458
DO - 10.1111/ggi.14458
M3 - Letter
C2 - 35986506
AN - SCOPUS:85136491959
JO - Geriatrics and Gerontology International
JF - Geriatrics and Gerontology International
SN - 1447-0594
ER -